Catamaran Introducing Innovative Clinical Outcomes-Based Program for Hepatitis C Treatment

- Company Selects Gilead Sciences as its Exclusive Hepatitis C Treatment Provider -
- Program Offered Exclusively Through Company's Specialty Pharmacy, BriovaRx^® -

SCHAUMBURG, IL, Feb. 3, 2015 /CNW/ - Catamaran Corp. (NASDAQ: CTRX, TSX: CCT), a leading provider of pharmacy benefit management (PBM) services and technology, today announced that it is introducing a new clinical outcomes-based program for hepatitis C treatment through its specialty pharmacy, BriovaRx^®.

This new program will provide clients of Catamaran and BriovaRx an innovative new approach to hepatitis C treatment. Centered on producing positive health outcomes, the program will allow for overall treatment costs to take into account clinical results. Patients will be monitored during their entire treatment regimen through their participation in BriovaRx's Hepatitis C Patient Management Program in order to support full adherence.

"When looking for a hepatitis C partner, our goal was not only to ensure the best possible value for the treatment cost alone, but also to promote the best possible health outcomes for our patients," said Albert Thigpen, SVP, Industry Relations & Supply Chain Management, Catamaran. "This innovative strategy supports Catamaran's view that a smarter approach to medicine has the power to lower overall healthcare costs and promotes optimal outcomes over the long-term."

Gilead Sciences, Inc.'s hepatitis C treatments, Harvoni and Sovaldi, are the exclusive options on Catamaran's National and Value Formularies. Catamaran's commercial clients will be eligible to participate in this clinical outcomes-based program for hepatitis C if they utilize one of these formularies or have a custom formulary and opt-in to the program.

"Catamaran and BriovaRx are rooted in delivering a more integrated healthcare experience for patients through a holistic and personalized approach," said, Sumit Dutta, M.D., M.B.A., Senior Vice President and Chief Medical Officer, Catamaran. "Our clinical outcomes-based program for hepatitis C supports this mission, empowering our nurses and pharmacists to partner with patients in a way that truly drives better health outcomes and ensures these high-cost therapies accomplish what they were designed to do."

To offer patients personalized care and achieve higher persistency and adherence rates, BriovaRx employs a variety of programs to aid patients. BriovaRx's Hepatitis C Patient Management Program features a nursing team that creates an individualized care plan for each patient based on the complexity of their condition and co-morbidities. Offerings like this have helped increase adherence and persistency for patients, contributing to overall cost savings and improved clinical outcomes.

About Catamaran

Catamaran, the industry's fastest-growing pharmacy benefits manager, helps organizations and the communities they serve take control of prescription drug costs. Managing more than 350 million prescriptions each year on behalf of over 32 million members, our flexible, holistic solutions improve patient care and empower individuals to take charge of their health. Processing one in every five prescription claims in the U.S., Catamaran's skill and scale deliver compelling financial results and sustainable improvement in the overall health of members. Catamaran is headquartered in Schaumburg, Ill., with multiple locations in the U.S. and Canada. For more information, please visit CatamaranRx.com, and for industry news and information, follow Catamaran on Twitter, @CatamaranCorp.

SOURCE Catamaran

Lauren Denz
Media Relations
Catamaran
Tel: [phone]
[email protected]

Tony Perkins
Investor Relations
Catamaran
Tel: [phone]
[email protected]